---
document_datetime: 2025-12-02 05:36:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/oyavas.html
document_name: oyavas.html
version: success
processing_time: 0.1085848
conversion_datetime: 2025-12-28 18:27:55.844886
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Oyavas

[RSS](/en/individual-human-medicine.xml/67420)

##### Authorised

This medicine is authorised for use in the European Union

bevacizumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Oyavas](#news-on)
- [More information on Oyavas](#more-information-on-oyavas-932)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Oyavas is a cancer medicine that is used to treat adults with the following cancers:

- cancer of the colon (large bowel) or the rectum, when it has spread to other parts of the body;
- breast cancer that has spread to other parts of the body;
- a type of lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Oyavas can be used in non-small cell lung cancer unless the cancer originates in cells called squamous cells;
- cancer of the kidney (renal cell carcinoma) that is advanced or has spread elsewhere;
- cancer of the ovary or associated structures (the fallopian tube that carries the egg from the ovary to the womb, and the peritoneum, the membrane that lines the abdomen) that is advanced or has come back after treatment;
- cancer of the cervix (the neck of the womb) that has persisted or come back after treatment, or has spread to other parts of the body.

Oyavas is used in combination with other cancer medicines, depending on the nature of any previous treatments or the presence of mutations (genetic changes) in the cancer that affect how well particular medicines work.

Oyavas is a 'biosimilar medicine'. This means that Oyavas is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Oyavas is Avastin. For more information on biosimilar medicines, see [here](/en/biosimilar-medicines-overview) .

Oyavas contains the active substance bevacizumab.

Expand section

Collapse section

## How is Oyavas used?

Oyavas can only be obtained with a prescription and treatment should be supervised by a doctor who has experience in the use of cancer medicines.

Oyavas is given by infusion (drip) into a vein. The first infusion of Oyavas should last 90 minutes, but subsequent infusions may be given more quickly if the earlier infusion has not caused unacceptable side effects. The dose depends on the patient's weight, the type of cancer being treated and the other cancer medicines being used. Treatment is continued for as long as the patient benefits from it. The doctor may interrupt or stop treatment if the patient develops certain side effects.

For more information about using Oyavas, see the package leaflet or contact your doctor or pharmacist.

## How does Oyavas work?

The active substance in Oyavas, bevacizumab, is a monoclonal antibody (a type of protein) that has been designed to attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and makes new blood vessels grow. By attaching to VEGF, Oyavas stops its effect. As a result, the cancer cannot develop its own blood supply and cancer cells are starved of oxygen and nutrients, helping to slow down the growth of tumours.

## What benefits of Oyavas have been shown in studies?

Laboratory studies comparing Oyavas with Avastin have shown that the active substance in Oyavas is highly similar to that in Avastin in terms of structure, purity and biological activity. Studies have also shown that giving Oyavas produces similar levels of the active substance in the body to giving Avastin.

In addition, a study involving 627 patients with advanced non-small cell lung cancer showed that Oyavas was as effective as Avastin when given with the cancer medicines paclitaxel and carboplatin. The cancer responded to treatment in 40% of those given Oyavas and 45% of those given Avastin, which was considered comparable.

Because Oyavas is a biosimilar medicine, the studies on effectiveness and safety of bevacizumab carried out with Avastin do not all need to be repeated for Oyavas.

## What are the risks associated with Oyavas?

The safety of Oyavas has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Avastin.

The most common side effects with bevacizumab (which may affect more than 1 in 10 people) are hypertension (high blood pressure), tiredness or asthenia (weakness), diarrhoea and abdominal (belly) pain. The most serious side effects are gastrointestinal perforation (hole in the gut wall), haemorrhage (bleeding) and arterial thromboembolism (blood clots in the arteries). For the full list of all side effects reported with Oyavas, see the package leaflet.

Oyavas must not be used in people who are hypersensitive (allergic) to bevacizumab or any of the other ingredients, to Chinese hamster ovary cell products or other recombinant (genetically engineered) antibodies. It must not be given to pregnant women.

## Why is Oyavas authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Oyavas has a highly similar structure, purity and biological activity to Avastin and is distributed in the body in the same way. In addition, studies in non-small cell lung cancer have shown that the safety and effectiveness of Oyavas is equivalent to that of Avastin in this indication.

All these data were considered sufficient to conclude that Oyavas will behave in the same way as Avastin in terms of effectiveness and safety in its authorised uses. Therefore, the Agency's view was that, as for Avastin, the benefits of Oyavas outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Oyavas?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oyavas have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Oyavas are continuously monitored. Side effects reported with Oyavas are carefully evaluated and any necessary action taken to protect patients.

## Other information about Oyavas

Oyavas received a marketing authorisation valid throughout the EU on 26 March 2021.

Oyavas : EPAR - Medicine overview

Reference Number: EMA/64627/2021

English (EN) (116.6 KB - PDF)

**First published:** 15/04/2021

[View](/en/documents/overview/oyavas-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-135)

български (BG) (167.86 KB - PDF)

**First published:**

15/04/2021

[View](/bg/documents/overview/oyavas-epar-medicine-overview_bg.pdf)

español (ES) (143.67 KB - PDF)

**First published:**

15/04/2021

[View](/es/documents/overview/oyavas-epar-medicine-overview_es.pdf)

čeština (CS) (167.63 KB - PDF)

**First published:**

15/04/2021

[View](/cs/documents/overview/oyavas-epar-medicine-overview_cs.pdf)

dansk (DA) (144.2 KB - PDF)

**First published:**

15/04/2021

[View](/da/documents/overview/oyavas-epar-medicine-overview_da.pdf)

Deutsch (DE) (147.85 KB - PDF)

**First published:**

15/04/2021

[View](/de/documents/overview/oyavas-epar-medicine-overview_de.pdf)

eesti keel (ET) (131.63 KB - PDF)

**First published:**

15/04/2021

[View](/et/documents/overview/oyavas-epar-medicine-overview_et.pdf)

ελληνικά (EL) (168.62 KB - PDF)

**First published:**

15/04/2021

[View](/el/documents/overview/oyavas-epar-medicine-overview_el.pdf)

français (FR) (145.04 KB - PDF)

**First published:**

15/04/2021

[View](/fr/documents/overview/oyavas-epar-medicine-overview_fr.pdf)

hrvatski (HR) (164.17 KB - PDF)

**First published:**

15/04/2021

[View](/hr/documents/overview/oyavas-epar-medicine-overview_hr.pdf)

italiano (IT) (142.85 KB - PDF)

**First published:**

15/04/2021

[View](/it/documents/overview/oyavas-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (173.51 KB - PDF)

**First published:**

15/04/2021

[View](/lv/documents/overview/oyavas-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (165.27 KB - PDF)

**First published:**

15/04/2021

[View](/lt/documents/overview/oyavas-epar-medicine-overview_lt.pdf)

magyar (HU) (165.26 KB - PDF)

**First published:**

15/04/2021

[View](/hu/documents/overview/oyavas-epar-medicine-overview_hu.pdf)

Malti (MT) (168.19 KB - PDF)

**First published:**

15/04/2021

[View](/mt/documents/overview/oyavas-epar-medicine-overview_mt.pdf)

Nederlands (NL) (145.18 KB - PDF)

**First published:**

15/04/2021

[View](/nl/documents/overview/oyavas-epar-medicine-overview_nl.pdf)

polski (PL) (170.09 KB - PDF)

**First published:**

15/04/2021

[View](/pl/documents/overview/oyavas-epar-medicine-overview_pl.pdf)

português (PT) (144.3 KB - PDF)

**First published:**

15/04/2021

[View](/pt/documents/overview/oyavas-epar-medicine-overview_pt.pdf)

română (RO) (164.13 KB - PDF)

**First published:**

15/04/2021

[View](/ro/documents/overview/oyavas-epar-medicine-overview_ro.pdf)

slovenčina (SK) (166.35 KB - PDF)

**First published:**

15/04/2021

[View](/sk/documents/overview/oyavas-epar-medicine-overview_sk.pdf)

slovenščina (SL) (163.19 KB - PDF)

**First published:**

15/04/2021

[View](/sl/documents/overview/oyavas-epar-medicine-overview_sl.pdf)

Suomi (FI) (141.36 KB - PDF)

**First published:**

15/04/2021

[View](/fi/documents/overview/oyavas-epar-medicine-overview_fi.pdf)

svenska (SV) (141.87 KB - PDF)

**First published:**

15/04/2021

[View](/sv/documents/overview/oyavas-epar-medicine-overview_sv.pdf)

Oyavas : EPAR - Risk-management-plan summary

English (EN) (31.75 KB - PDF)

**First published:** 15/04/2021

[View](/en/documents/rmp-summary/oyavas-epar-risk-management-plan-summary_en.pdf)

## Product information

Oyavas : EPAR - Product information

English (EN) (423.93 KB - PDF)

**First published:** 15/04/2021

**Last updated:** 23/04/2024

[View](/en/documents/product-information/oyavas-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-558)

български (BG) (434.68 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/bg/documents/product-information/oyavas-epar-product-information_bg.pdf)

español (ES) (422.05 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/es/documents/product-information/oyavas-epar-product-information_es.pdf)

čeština (CS) (401.36 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/cs/documents/product-information/oyavas-epar-product-information_cs.pdf)

dansk (DA) (399.38 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/da/documents/product-information/oyavas-epar-product-information_da.pdf)

Deutsch (DE) (435.61 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/de/documents/product-information/oyavas-epar-product-information_de.pdf)

eesti keel (ET) (397.64 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/et/documents/product-information/oyavas-epar-product-information_et.pdf)

ελληνικά (EL) (458.53 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/el/documents/product-information/oyavas-epar-product-information_el.pdf)

français (FR) (415.28 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/fr/documents/product-information/oyavas-epar-product-information_fr.pdf)

hrvatski (HR) (415.26 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/hr/documents/product-information/oyavas-epar-product-information_hr.pdf)

íslenska (IS) (425.4 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/is/documents/product-information/oyavas-epar-product-information_is.pdf)

italiano (IT) (421.94 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/it/documents/product-information/oyavas-epar-product-information_it.pdf)

latviešu valoda (LV) (418.79 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/lv/documents/product-information/oyavas-epar-product-information_lv.pdf)

lietuvių kalba (LT) (427.41 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/lt/documents/product-information/oyavas-epar-product-information_lt.pdf)

magyar (HU) (444.69 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/hu/documents/product-information/oyavas-epar-product-information_hu.pdf)

Malti (MT) (499.12 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/mt/documents/product-information/oyavas-epar-product-information_mt.pdf)

Nederlands (NL) (422.26 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/nl/documents/product-information/oyavas-epar-product-information_nl.pdf)

norsk (NO) (411.08 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/no/documents/product-information/oyavas-epar-product-information_no.pdf)

polski (PL) (455.31 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/pl/documents/product-information/oyavas-epar-product-information_pl.pdf)

português (PT) (419.51 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/pt/documents/product-information/oyavas-epar-product-information_pt.pdf)

română (RO) (440.5 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/ro/documents/product-information/oyavas-epar-product-information_ro.pdf)

slovenčina (SK) (425.5 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/sk/documents/product-information/oyavas-epar-product-information_sk.pdf)

slovenščina (SL) (418.7 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/sl/documents/product-information/oyavas-epar-product-information_sl.pdf)

Suomi (FI) (417.27 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/fi/documents/product-information/oyavas-epar-product-information_fi.pdf)

svenska (SV) (417.93 KB - PDF)

**First published:**

15/04/2021

**Last updated:**

23/04/2024

[View](/sv/documents/product-information/oyavas-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0031/G 22/04/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Oyavas : EPAR - All authorised presentations

English (EN) (21.44 KB - PDF)

**First published:** 15/04/2021

[View](/en/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-493)

български (BG) (42.19 KB - PDF)

**First published:**

15/04/2021

[View](/bg/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.38 KB - PDF)

**First published:**

15/04/2021

[View](/es/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_es.pdf)

čeština (CS) (33.6 KB - PDF)

**First published:**

15/04/2021

[View](/cs/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.08 KB - PDF)

**First published:**

15/04/2021

[View](/da/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (16.34 KB - PDF)

**First published:**

15/04/2021

[View](/de/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (16.13 KB - PDF)

**First published:**

15/04/2021

[View](/et/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.91 KB - PDF)

**First published:**

15/04/2021

[View](/el/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_el.pdf)

français (FR) (16.21 KB - PDF)

**First published:**

15/04/2021

[View](/fr/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (37.25 KB - PDF)

**First published:**

15/04/2021

[View](/hr/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (15.99 KB - PDF)

**First published:**

15/04/2021

[View](/is/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.49 KB - PDF)

**First published:**

15/04/2021

[View](/it/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.62 KB - PDF)

**First published:**

15/04/2021

[View](/lv/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.33 KB - PDF)

**First published:**

15/04/2021

[View](/lt/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (24.91 KB - PDF)

**First published:**

15/04/2021

[View](/hu/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (36.47 KB - PDF)

**First published:**

15/04/2021

[View](/mt/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (16.2 KB - PDF)

**First published:**

15/04/2021

[View](/nl/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.29 KB - PDF)

**First published:**

15/04/2021

[View](/no/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_no.pdf)

polski (PL) (38.68 KB - PDF)

**First published:**

15/04/2021

[View](/pl/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.38 KB - PDF)

**First published:**

15/04/2021

[View](/pt/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.46 KB - PDF)

**First published:**

15/04/2021

[View](/ro/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (35.05 KB - PDF)

**First published:**

15/04/2021

[View](/sk/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.74 KB - PDF)

**First published:**

15/04/2021

[View](/sl/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.46 KB - PDF)

**First published:**

15/04/2021

[View](/fi/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.29 KB - PDF)

**First published:**

15/04/2021

[View](/sv/documents/all-authorised-presentations/oyavas-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Oyavas Active substance bevacizumab International non-proprietary name (INN) or common name bevacizumab Therapeutic area (MeSH)

- Colorectal Neoplasms
- Breast Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms

Anatomical therapeutic chemical (ATC) code L01FG01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

Oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.

Oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Oyavas in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.

Oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology.

Oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).

Oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.

Oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).

Oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.

Oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents (see Section 5.1).

Oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005556

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

STADA Arzneimittel AG

Stadastrasse 2-18

Opinion adopted 28/01/2021 Marketing authorisation issued 26/03/2021 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Oyavas : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (194.58 KB - PDF)

**First published:** 28/01/2022

**Last updated:** 10/11/2025

[View](/en/documents/procedural-steps-after/oyavas-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

Oyavas-H-C-PSUSA-00000403-202202 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/921971/2022

English (EN) (125.12 KB - PDF)

**First published:** 05/01/2023

[View](/en/documents/scientific-conclusion/oyavas-h-c-psusa-00000403-202202-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Oyavas : EPAR - Public assessment report

Adopted

Reference Number: EMA/197736/2021 Corr.

English (EN) (3.48 MB - PDF)

**First published:** 15/04/2021

**Last updated:** 06/05/2021

[View](/en/documents/assessment-report/oyavas-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Oyavas

Adopted

Reference Number: EMA/CHMP/27606/2021

English (EN) (101.92 KB - PDF)

**First published:** 01/02/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-oyavas_en.pdf)

#### News on Oyavas

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021) 29/01/2021

#### More information on Oyavas

- [Biosimilar medicines: Overview](/en/human-regulatory-overview/biosimilar-medicines-overview)

**This page was last updated on** 10/11/2025

## Share this page

[Back to top](#main-content)